Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

NCT02229396 on ClinicalTrials.gov · last registry update 2018-12-31

Finished 26 April 2016, after enrolling 695 people. Primary outcome, as filed: Change in HbA1c From Baseline to Week 28. exenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 695
Started: 2014-09-04
Primary completion: 2016-04-26 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c From Baseline to Week 28

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.